The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity.
Urgency Urinary Incontinence
The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity.
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233
University of California, San Diego, San Diego, California, United States, 92093
Howard University, Washington, District of Columbia, United States, 20059
University of New Mexico, Albuquerque, New Mexico, United States, 87131
Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States, 02905
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
FEMALE
Yes
Women and Infants Hospital of Rhode Island,
Vivian Sung, MD, MPH, PRINCIPAL_INVESTIGATOR, Women and Infants Hospital of Rhode Island
Peter Jeppson, MD, PRINCIPAL_INVESTIGATOR, University of New Mexico
2027-07-15